Cancer targeting Gene-Viro-Therapy of liver carcinoma by dual-regulated oncolytic adenovirus armed with TRAIL gene
文献类型：期刊论文
| 作者 | Cao, X; Yang, M; Wei, RC; Zeng, Y; Gu, JF; Huang, WD; Yang, DQ; Li, HL; Ding, M; Wei, N |
| 刊名 | GENE THERAPY
 |
| 出版日期 | 2011 |
| 卷号 | 18期号:8页码:765-777 |
| 关键词 | cancer targeting Gene-Viro-Therapy dual-regulated oncolytic adenovirus tumor necrosis factor-related apoptosis-inducing ligand autophagy apoptosis |
| 通讯作者 | Liu, XY (reprint author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Mol Cell Biol Lab, 320 Yueyang Rd, Shanghai 200031, Peoples R China.,xyliu@sibs.ac.cn |
| 英文摘要 | Liver cancer is a common and aggressive malignancy, but available treatment approaches remain suboptimal. Cancer targeting Gene-Viro-Therapy (CTGVT) has shown excellent anti-tumor effects in a preclinical study. CTGVT takes advantage of both gene therapy and virotherapy by incorporating an anti-tumor gene into an oncolytic virus vector. Potent anti-tumor activity is achieved by virus replication and exogenous expression of the anti-tumor gene. A dual-regulated oncolytic adenoviral vector designated Ad.AFP.E1A.E1B (Delta 55) (Ad.AFP.D55 for short thereafter) was constructed by replacing the native viral E1A promoter with the simian virus 40 enhancer/alpha-fetoprotein (AFP) composite promoter (AFPep) based on an E1B-55K-deleted construct, ZD55. Ad.AFP.D55 showed specific replication and cytotoxicity in AFP-positive hepatoma cells. It also showed enhanced safety in normal cells when compared with the mono-regulated vector ZD55. To improve the anti-hepatoma activities of the virus, the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene was introduced into Ad.AFP.D55. Ad.AFP.D55-TRAIL exhibited remarkable anti-tumor activities in vitro and in vivo. Treatment with Ad.AFP.D55-TRAIL can induce both autophagy owing to the Ad.AFP.D55 vector and caspase-dependent apoptosis owing to the TRAIL protein. Therefore, Ad.AFP.D55-TRAIL could be a potential anti-hepatoma agent with anti-tumor activities due to AFP-specific replication and TRAIL-induced apoptosis. Gene Therapy (2011) 18, 765-777; doi:10.1038/gt.2011.16; published online 17 March 2011 |
| 学科主题 | Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine |
| 类目[WOS] | Biochemistry & Molecular Biology ; Biotechnology & Applied Microbiology ; Genetics & Heredity ; Medicine, Research & Experimental |
| 关键词[WOS] | HUMAN HEPATOCELLULAR-CARCINOMA ; PROGRAMMED CELL-DEATH ; ANTITUMOR-ACTIVITY ; ALPHA-FETOPROTEIN ; TUMOR-CELLS ; COLORECTAL-CANCER ; SURVIVIN PROMOTER ; MALIGNANT GLIOMA ; HUMAN HEPATOMA ; SV40 ENHANCER |
| 收录类别 | SCI |
| 语种 | 英语 |
| WOS记录号 | WOS:000293779500003 |
| 版本 | 出版稿 |
| 源URL | [http://202.127.25.143/handle/331003/837]  |
| 专题 | 上海生化细胞研究所_上海生科院生化细胞研究所 |
| 推荐引用方式 GB/T 7714 | Cao, X,Yang, M,Wei, RC,et al. Cancer targeting Gene-Viro-Therapy of liver carcinoma by dual-regulated oncolytic adenovirus armed with TRAIL gene[J]. GENE THERAPY,2011,18(8):765-777. |
| APA | Cao, X.,Yang, M.,Wei, RC.,Zeng, Y.,Gu, JF.,...&Liu, XY.(2011).Cancer targeting Gene-Viro-Therapy of liver carcinoma by dual-regulated oncolytic adenovirus armed with TRAIL gene.GENE THERAPY,18(8),765-777. |
| MLA | Cao, X,et al."Cancer targeting Gene-Viro-Therapy of liver carcinoma by dual-regulated oncolytic adenovirus armed with TRAIL gene".GENE THERAPY 18.8(2011):765-777. |
入库方式： OAI收割
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。